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Ocular developmental anomalies (ODA) such as anophthalmia/microphthalmia (AM) or anterior segment dysgenesis
(ASD) have an estimated combined prevalence of 3.7 in 10,000 births. Mutations in SOX2 are themost frequent contributors
to severe ODA, yet account for a minority of the genetic drivers. To identify novel ODA loci, we conducted targeted high-
throughput sequencing of 407 candidate genes in an initial cohort of 22 sporadic ODA patients. Patched 1 (PTCH1), an in-
hibitor of sonic hedgehog (SHH) signaling, harbored an enrichment of rare heterozygous variants in comparison to either
controls, or to the other candidate genes (four missense and one frameshift); targeted resequencing of PTCH1 in a second
cohort of 48 ODA patients identified two additional rare nonsynonymous changes. Using multiple transient models and
a CRISPR/Cas9-generated mutant, we show physiologically relevant phenotypes altering SHH signaling and eye develop-
ment upon abrogation of ptch1 in zebrafish for which in vivo complementation assays using these models showed that all
six patient missense mutations affect SHH signaling. Finally, through transcriptomic and ChIP analyses, we show that
SOX2 binds to an intronic domain of the PTCH1 locus to regulate PTCH1 expression, findings that were validated both in vitro
and in vivo. Together, these results demonstrate that PTCH1 mutations contribute to as much as 10% of ODA, identify the
SHH signaling pathway as a novel effector of SOX2 activity during human ocular development, and indicate that ODA is
likely the result of overactive SHH signaling in humans harboring mutations in either PTCH1 or SOX2.
[Supplemental material is available for this article.]
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Severe congenital ocular malformations, including the reduction
of eye size and anterior chamber anomalies at birth, are rare, with
an estimated combined prevalence of 3.7 in 10,000 births
(Bermejo andMartinez-Frias 1998). Ocular developmental anoma-
lies (ODA) suchas anophthalmia/microphthalmia (AM)oranterior
segment dysgenesis (ASD) are underscored by extensive genetic
heterogeneity, phenotypic variability, and nonpenetrance.
Anophthalmia refers to thecompleteabsenceofocular tissue in
the orbit (true anophthalmia), or the absence of ocular tissue upon
clinical examination (clinical anophthalmia). Microphthalmia
corresponds to a globe with a total axial length that is at least two
standard deviations below the mean for age (<19 mm in a one-
year-old child, <21 mm in an adult) (Weiss et al. 1989; Verma and
Fitzpatrick 2007). To date,more than20 genes have been implicated
inAMinhumans.Mutations in SOX2 are themost frequent contrib-
utors to severe ODA (Fantes et al. 2003), yet account for a minority
(10%–15%) of the genetic drivers (Verma and Fitzpatrick 2007),
while other genes aremore rarely involved. In AM cases, the genetic
basis, eithermonogenicorchromosomal, is identified in∼20%–40%
of individuals who undergo genetic testing (Slavotinek 2011;
Chassaing et al. 2014). ASD disorders encompass a wide variety of
developmental conditions affecting the cornea, iris, and lens in-
cluding corneal opacity, posterior embryotoxon, iris hypoplasia,
corectopia or polycoria, and adhesions between the iris and cornea
or lens and cornea (Reis and Semina 2011). Two clinically distinct
ASD disorders have been recognized as separate entities based on
unique combinations of diagnostic criteria: Axenfeld-Rieger anoma-
ly (iris hypoplasia, posterior embryotoxon, iris hypoplasia, corecto-
pia/polycoria, and/or irido-corneal adhesions) and Peters anomaly
(corneal opacity, defects in the posterior layers of the cornea, and
lenticulo-corneal and/or irido-corneal adhesions). Causative muta-
tions are identified in ∼40% of individuals with Axenfeld-Rieger
anomaly, mainly in two genes, PITX2 and FOXC1 (Pasutto et al.
2015). Despite the fact that thirteen genes have been associated
with Peters anomaly, the genetic basis of this ocular anomaly re-
mains unknown in the majority of cases (Weh et al. 2014).
Classical genetics approaches were successful to discover the
firstODAgenes. Linkage analysis studies allowed the identification
of only few genes (Ferda Percin et al. 2000; Pasutto et al. 2007). The
reason is most of the pedigrees available are small; therefore, the
chromosomal regions that segregate with the disease are usually
numerous and not reaching genome-wide significance. Positional
candidate gene approaches pursuant to the identification of chro-
mosomal abnormalities inODAcases, or candidate gene approach-
es related to phenotype have yielded some gene discovery results
such as SOX2 and OTX2 (Fantes et al. 2003; Ragge et al. 2005a).
However, they have similarly reached an impasse toward identify-
ing novel causal or contributory loci. In past years, the develop-
ment of next-generation sequencing technologies has allowed
the identification of several new ODA genes, including ALDH1A3
and RARB (Fares-Taie et al. 2013; Srour et al. 2013). To identify nov-
el ODA loci, we harnessed the power of next-generation sequenc-
ing technologies and conducted targeted high-throughput
sequencing of a subset of candidate genes with a potential role in
eye development, in a cohort of 22 sporadic ODA patients.
Results
Targeted resequencing identifies a significantly enriched
mutational burden in PTCH1
We selected 407 candidate genes (Supplemental Table 1) involved
in ocular development for targeted exon liquid capture followedby
massively parallel sequencing.We screened 22 unrelated individu-
als with ODA and mutation negative for SOX2, OTX2, RAX, and
VSX2 and two positive control individuals (with knownmutations
in either STRA6or inVSX2). These affected individuals had isolated
ASD (n = 6), or AM that was isolated (n = 4), associated with ASD (n
= 6), or coincident with coloboma (n = 6) (Supplemental Table 2).
We identified∼2500 variants in each patient; after stringent bioin-
formatic filtering that focused exclusively on alleles that were (1)
absent from dbSNP132 (http://www.ncbi.nlm.nih.gov/projects/
SNP/; Sherry et al. 2001), HapMap (http://hapmap.ncbi.nlm.nih.
gov/; The International HapMap 3 Consortium et al. 2010), 1000
Genomes (http://www.1000genomes.org/; The 1000 Genomes
Project Consortium 2015), and our in-house exomes; and (2)
predicted in silico to be deleterious (Supplemental Table 3), we ob-
served 0–5 variants per individual in a total of 46 loci. These genes
harbored variation in the following locus-widedistribution: >1 var-
iant/gene in 10 genes (Fig. 1A; Supplemental Tables 4, 5); 1 variant/
gene in 36 genes; the remaining 361 genes were bereft of rare func-
tional variants predicted to be deleterious (Supplemental Table 4,
discussed in the Supplemental Note).
Among these 46 loci, PTCH1 carried the greatest mutational
burden and was the most significantly enriched for rare putative
pathogenic variants in the 22 individuals from the ODA cohort
and in the two positive control individuals C1 and C2 in compar-
ison to 13,006 control chromosomes in the Exome Variant Server
(EVS) (P < 0.0001; Table 1; Fig. 1A,B) (http://evs.gs.washington.
edu/EVS/; Fu et al. 2013) and remained nominally significant
after correction for the 407 target gene set (P = 0.04). Notably,
the only other genes harboring an enrichment of rare variants pre-
dicted to be pathogenic in the 24 patients were VSX2 and STRA6,
both ofwhichhave been identified previously as rareODAcontrib-
utors (Ferda Percin et al. 2000; Chassaing et al. 2009) and were
mutated in the positive control individuals C1 and C2, respective-
ly (P < 0.01 vs. 13,006 EVS chromosomes) (Fig. 1A; Supplemental
Table 5). Upon exclusion of each of C1 and C2 from the muta-
tional burden analysis, PTCH1was the only gene that carried a sig-
nificant enrichment of pathogenic variants in the 22 ODA cases
with previously unknown genetic etiology (P < 0.0001 vs. EVS)
(Fig. 1A).
Four individuals harbored rare PTCH1 heterozygous changes
predicted to be deleterious (Table 1; Fig. 1B). One patient with
microphthalmia, cataract, and sclerocornea (P5) had a frameshift-
ing deletion (c.4delG, p.Glu2Asnfs∗9) in exon 1 of PTCH1 isoform
NP_001077072. Patient P20, affected with a bilateral Peters
anomaly, harbored a heterozygous p.Tyr1316Cys change. Two ad-
ditional unrelated patients with colobomatous microphthalmia,
corpus callosum abnormality, and atrial septal defects (P8 and
P15) harbored c.3191C>T (p.Thr1064Met) and c.3241G>A
(p.Val1081Met) changes. With the exception of P5, for whom
we were unable to perform segregation analysis, we determined
that each of these three PTCH1 mutations was inherited from an
asymptomatic parent (Table 1; Supplemental Table 4), consistent
with incomplete penetrance.
Because of the significant enrichment of PTCH1 variants in
our first-pass filtering strategy, and cognizant of the imperfect sen-
sitivity and specificity of prediction algorithms, we returned to the
set of rare variants remaining prior to in silico predictions. We
found two additional heterozygous rare PTCH1 missense variants
filtered out initially because they were considered benign by
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/; Adzhubei
et al. 2010). Individual P17, presenting with a bilateral Axenfeld-
Rieger malformation, had a c.3889C>T (p.Arg1297Trp) mutation.
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Additionally, we identified a heterozygous p.Asp436Asn change in
the control sample C2 (Table 1; Fig. 1B).
In vivo assay of variant pathogenicity shows that PTCH1 variants
are deleterious
The significant enrichment of mutational burden in the 24 cases
compared to 6500 EVS controls (P < 0.001), amino acid conserva-
tion, and in silico prediction evidencewere suggestive but not con-
clusive with regard to the deleterious effect of the PTCH1missense
variants identified in the ODA cohort (Table 1; Supplemental Fig.
1). Moreover, the observed incomplete penetrance posed interpre-
tive challenges. Therefore, we evaluated the effect of all discovered
alleles in vivo. PTCH1 is a transmembrane-dependent receptor
which functionswith SHHas part of a dosage-sensitive pathway re-
sulting in activation of downstream target genes, including the
Smoothened (SMO) coreceptor, PTCH1 itself, andGli transcription
factors GLI1, GLI2, and GLI3 (Villavicencio et al. 2000). SHH sig-
naling is a key regulator of somite patterning (Bumcrot and
McMahon 1995), and numerous zebrafish models of the SHH
pathway including shh (Schauerte et al. 1998), smo (Varga et al.
2001), suppressor of fused (sufu) (Wolff et al. 2003; Koudijs et al.
2005), patched 2 (ptch2, referred to previously as ptc1 [Koudijs
et al. 2008]), and kif7 (Tay et al. 2005) display a visiblymore obtuse
angle of the somitic chevron compared towild-type (WT) controls.
We have shown previously that in vivo complementation studies
of human mutations in SHH effector molecules using somite de-
fects as a phenotypic readout are a robust assay to determine allele
pathogenicity (Putoux et al. 2011). We therefore employed this
strategy to test the ability of human mRNAs harboring the ODA
PTCH1 missense mutations to rescue ptch1 MO-induced somite
angle defects in comparison to that of WT.
Using reciprocal BLAST, we confirmed that the single ortho-
log of human PTCH1 is located on Danio rerio Chromosome 8
(73% identity, 80% similarity; human versus zebrafish protein);
this gene, initially named ptc2, is mutated in the zebrafish lepre-
chaun (lep) mutant (Koudijs et al. 2005) but will hereafter be re-
ferred to as ptch1. This locus is distinctly different from ptc1, the
zebrafish ortholog of human PTCH2 that is mutated in the zebra-
fish blowout (blw) mutant (Koudijs et al. 2008), and is now referred
to as ptch2. We obtained a previously published splice-blocking
(sb) morpholino antisense oligonucleotide (MO) targeting the
exon 3 splice donor site (Koudijs et al. 2008), and we detected a
partial suppression of ptch1 expression by RT-PCR analysis of sb1
MO-injected whole-embryo lysates (Supplemental Fig. 2A). Even
so, we observed somite phenotypes characteristic of Shh defects
inWT embryos injected with 12 ng of ptch1 sb1MO (81.5° degrees
vs. 97.5° degrees for control vs. ptch1 sb1 MO; P < 0.0001) (Fig. 2;
Supplemental Table 7). Importantly, co-injection of 100 pg of
capped human PTCH1WTmRNA resulted in a significant amelio-
ration of the somite defect (85.9° vs. 97.5° for WT rescue vs. MO;
P < 0.0001).
We next evaluated the five missense mutations
(p.Asp436Asn, p.The1064Met, p.Val1081Met, p.Arg1297Trp,
p.Tyr1316Cys) identified among the 22 patients and two control
ODA individuals. As a measure of the sensitivity and relevance
of this assay, we also evaluated known deleterious variants that
have been proposed to be pathogenic based on either genetic evi-
dence or functional evaluation of SHH pathway readout. As such,
we tested the effect of human PTCH1 mRNA carrying the known
pathogenic p.Thr1052Met change, associated previously with a
holoprosencephaly (HPE)-like phenotype (including bilateral
microphthalmia) and normalMRI (Ribeiro et al. 2006) or with alo-
bar HPE (Ming et al. 2002).We also evaluated p.Leu360Arg, report-
ed previously as a loss-of-function variant that is unable to
complement PTCH1 function in murine Ptch1−/− fibroblast cells
(Bailey et al. 2003). Considering the possibility that the PTCH1 var-
iants in our ODA cohort could function as dominant negative al-
leles, we tested p.Gly509Val, a highly conserved change in the
sterol-sensing domain that confers a dominant negative effect in
Drosophila (Hime et al. 2004). As negative controls for the assay,
we evaluated a nonsynonymous change found commonly in pop-
ulation controls, p.Pro1315Leu, and a second C-terminal change,
p. Pro1125Leu, shown previously to restore SHH signaling readout
in vitro (Bailey et al. 2003). In contrast to the significant rescue
of the morphant phenotype resulting from co-injection of either
WT mRNA or the negative control mRNAs (p.Pro1125Leu
and p.Pro1315Leu), the morphant somite angle defect was
Figure 1. PTCH1 has a significantly enriched mutational burden in ocu-
lar developmental anomalies (ODA). (A) Mutational burden for all genes
harboring >1 rare predicted pathogenic variants in the initial cohort of
ODA compared to healthy control individuals from the Exome Variant
Server (EVS). Frequency of combined mutational burden is shown for
the 10 genes harboring multiple rare (<1% alternate allele frequency)
functional variants (frameshift, nonsense, and splicing variants were con-
sidered as damaging; missense variants were classified as damaging or
not based on PolyPhen-2) in either ODA cases including two positive con-
trols (n = 22 unknown + 2 positive controls; dark blue bars), or ODA test
cases alone (n = 22 unknown; light blue bars) vs. EVS controls (n = 6500;
green bars). P-values are indicated for the only three genes with a signifi-
cant enrichment in cases versus controls (χ2 test). (∗) VSX2 and STRA6
are previously identified causal genes in the positive control ODA samples,
C1 and C2, respectively; C1 also harbored variants in FRAS1 and NDST2.
(B) Schematic representation of the PTCH1 receptor with its extracellular
(EC), transmembrane (M), and intra-cellular domains (IC). The positions
of the PTCH1 mutations identified in ODA are represented with asterisks,
with the color indicating variant pathogenicity. The four variants enclosed
with boxes were identified in the initial discovery cohort. p.E2Nfs∗9 is spe-
cific to isoform NP_001077072 (purple), which is identical to NP_000255
(black) except for an alternate 66 amino acid region at the N terminus.
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significantly worse than WT rescue (P < 0.0001 for each co-injec-
tion vs. WT rescue) and either partially ameliorated or not signifi-
cantly different from ptch1 sb1 MO alone. We observed similar
results for the p.Thr1052Met change (associated with HPE) and
p.Leu360Arg (functional null) (Fig. 2; Supplemental Table 7).
Notably, co-injection of ptch1 sb1 MO with the mRNA bearing
the p.Asp436Asn change identified in control C2 showed pheno-
typic rescue similar to that of the WT and negative control
mRNAs, demonstrating that this change is benign. Unlike the
mRNA harboring the known dominant negative p.Gly509Val, in-
jection of WT or mutant mRNA in the absence of MO resulted in
no significant defects, arguing in favor of a loss-of-function rather
than a dominant-negative effect for the ODA-associated alleles.
Together, these results provided in vivo evidence that all rare mis-
sense variants identified in our ODA discovery cohort, as well
as the mutation associated with HPE, have a detrimental effect
on PTCH1 protein activity (Supplemental Table 7), while the
negative control variants p.Pro1125Leu, p.Pro1315Leu, and the
p.Asp436Asn change identified in a control patient had no detect-
able effect on protein function.
Pathogenic PTCH1 alleles are present in an independent
ODA cohort
Encouraged by these observations, we conducted bidirectional
Sanger sequencing of the coding regions of PTCH1 in an indepen-
dent cohort of 48 samples withODA.We identified two additional
rare heterozygous PTCH1 missense variants: p.Ile899Val in a pa-
tient with bilateral Peters anomaly, and p.Thr778Pro in an autoso-
mal dominant AM-ASD family, each ofwhichwas absent fromEVS
(Table 1; Fig. 1B; Supplemental Table 4). An in vivo functional as-
say of each of the two additional variants demonstrated that, sim-
ilar to the alleles found in our original cohort, both changes
resulted in partial loss of PTCH1 function (mean somite angle
Figure 2. PTCH1 variants identified in ODA patients are pathogenic. (A,B) Representative lateral images of uninjected control and ptch1 sb1MO-injected
live embryos taken at 36 h post-fertilization (hpf); dashed boxes are enlarged in the insets (right). Magnified panels show chevron-shaped somites (controls)
and abnormal-shaped somites (morphants), caused by aberrant Hedgehog signaling in the zebrafish myotome. Dashed blue lines indicate measurement
position (at the midpoint between the proximal hindgut and the anus) used for phenotypic scoring of embryo batches. (C) All six nonsynonymous PTCH1
variants identified in ODA cases were pathogenic as indicated by the inability of mutant mRNA to rescue the ptch1 MO-induced somite angle defects.
PTCH1 p.Thr1052Met, a rare variant (minor allele frequency in controls 0.001; n = 13,006 chromosomes [EVS]) reported previously in HPE, is also patho-
genic; p.Leu360Arg is a previously reported functional null. Rescue with a common PTCH1 p.Pro1315Leu encoding variant (rs357564; present in homo-
zygosity in 8% of controls; n = 12,568 chromosomes in EVS) was not significantly (NS) different fromwild type (WT), nor was a previously reported benign
variant p.Pro1125Leu change, providing support for the specificity of the assay. p.Gly509Val is a positive control for dominant negative effects. The mis-
sense variant p.Asp436Asn identified in the ODA control C2 was benign in this assay. Wemeasured 38–58 embryos per injection batch with blind scoring.
Asterisks indicate statistical differences betweenmutant andWT rescue (P < 0.0001; Student’s t-test). Error bars, SEM. See Supplemental Table 7 for somite
measurement data.
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90.0° and 94.7° for p.Thr778Pro and p.Ile899Val, respectively;
P < 0.0001 for each MO plus mutant mRNA co-injection versus
WT rescue) (Fig. 2; Supplemental Table 6). Combined, we identi-
fied a total of seven rare heterozygous PTCH1 variants (six mis-
sense and one frameshifting) in a total of 70 individuals with
ODA (10%) (Fig. 1B).
In vivo suppression of ptch1 results in microphthalmia
Concomitant with aberrant somite formation, defects in the
development of the visual system represent well-documented phe-
notypes in zebrafish SHH pathway component mutants. Impor-
tantly, zebrafish ENU mutant models of both patched homologs
display ocular abnormalities: ptch1 (lep/ptc2) mutants have vit-
reo-retinal abnormalities (Bibliowicz and Gross 2009); and muta-
tion of ptch2 (blw/ptc1) results in gross defects in eye morphology
with variably penetrant coloboma (Karlstrom et al. 1996; Lee
et al. 2008). To determine whether ptch1 suppression produced a
phenotype relevant to our ODA cohort, we evaluated ptch1 sb1
MO-injected embryos for eye size defects by measuring eye area
from lateral views at 3 d post-fertilization (dpf) and 5 dpf; consis-
tent with previous observations, we observed no significant eye
size differences between sb1 morphants versus controls (data not
shown; Koudijs et al. 2005). This is likely due to incomplete knock-
down of endogenous transcript (Supplemental Fig. 2A). Therefore,
we designed two additional MOs including a translation blocker
(tb) and a splice blocker (sb2) targeting the exon 5 splice donor
site of ptch1. RT-PCR monitoring of endogenous ptch1 transcript
in MO-injected embryos confirmed the higher efficiency of sb2
in suppressing WT ptch1 expression in comparison to sb1
(Supplemental Fig. 2B). Next, we injectedWT embryos with either
ptch1 sb2 or tb MOs; embryo batches were grown to 36 h post-fer-
tilization (hpf) and scored first for abnormal somitic shape. Similar
to ptch1 sb1 MO-injected embryos, either mRNA splicing (sb2) or
translational suppression (tb) resulted in obtuse somite angles sig-
nificantly broader than controls (85.2° vs. 95.4° [tb] or 97.4° [sb2]
for control vs. ptch1 tb or sb2 MOs, respectively; P < 0.0001)
(Supplemental Fig. 3).
We then aged embryos to 3 dpf and the eye area was assessed
as a percentage of WT eye area (Fig. 3A). We observed a significant
reduction in eye size in both ptch1 morphant batches (1.5 ng tb
MO; 2 ng sb2 MO; n = 42–52 embryos/injection; repeated three
times; P < 0.001), supporting the direct role of ptch1 in ocular de-
velopment. Importantly, this phenotype was validated using a
Figure 3. Suppression of ptch1 in vivo results in microphthalmia. (A) Representative lateral images of uninjected control and ptch1 tb, ptch1 sb2, or sox2
MO-injected embryos at 3 d post-fertilization (dpf) (top). Dashed yellow line indicates area of measurement used for quantification of eye size; morphant
measurements were normalized relative to control (bottom). (B) Representative lateral images of uninjected control and ptch1 guide RNA (gRNA)/Cas9
injected embryos at 3 dpf (top). ptch1 CRISPR F0 embryos were scored for eye size and retina size (bottom). (C) At 1 dpf, a representative sampling of
10 founders and two uninjected controls were selected and subjected to T7 endonuclease 1 (T7E1) assay. The appearance of T7E1 fragments < 100 bp
(marked by asterisks) indicate positive gRNA targeting of exon 6 in the ptch1 locus. No T7E1 fragments were detected in uninjected control embryos.
Of the 10 founders subjected to T7E1 assay, seven showed the presence of T7E1 fragments, indicating that ∼70% of founders have insertion/deletions
(indels) in the exon 6 region of ptch1. (D) Multiple sequence alignment of ptch1 reference sequence to ptch1-CRISPR variants generated from PCR ampli-
fication, subsequent TA cloning, and sequencing of ptch1-gRNA/Cas9 injected embryo #6. Black bold font marks the guide target, and the PAM recog-
nition motif is underlined. Seven PCR-cloned sequences are shown, representing three wild-type variants and all four changes detected. TA cloning
and sequencing of each founder embryo indicated 10%–65% mosaicism in individual fish (n = 5 assessed).
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CRISPR/Cas9 F0 mutant model (Fig. 3B–D). Injection of a guide
RNA targeting exon 6 of the ptch1 locus induces gene-disruptive
insertion-deletions (70% of embryos targeted; embryos with
>65% mosaicism were selected for phenotyping) and leads to a
significant reduction in eye size and retina size compared to con-
trols (P < 0.001) (Fig. 3B,C), as described for the ptch1lep mutant
(Bibliowicz and Gross 2009).
PTCH1 is regulated directly by the most frequently mutated ODA
protein, SOX2
Pursuant to the elevated prevalence of ODA patients with patho-
genic PTCH1 variants, we wondered if this locus might be linked
mechanistically to SOX2, as observed previously for other genes
implicated in disorders of ocular development (Kamachi et al.
2001; Danno et al. 2008). We asked whether PTCH1might be reg-
ulated transcriptionally by SOX2. First, using RNA in situ hybridi-
zation, we found that robust embryonic Ptch1 expression in the
neural retina and lens persists to later stages in the adult mouse
(Fig. 4), as observed in humans (Bakrania et al. 2008), and overlaps
the known expression pattern of SOX2 (Hever et al. 2006). Using a
physiologically relevant model of genetically modified murine
stem cells overexpressing Rax (Tabata et al. 2004), we suppressed
Sox2 and tested the abundance of Ptch1message; in biological trip-
licate experiments, we found that Ptch1 is up-regulated signifi-
cantly upon Sox2 suppression (P < 0.001) (Fig. 5A), suggesting
that the Ptch1 locus might be under the transcriptional regulation
of SOX2. We therefore performed chromatin immunoprecipita-
tion (ChIP)-seq on CCE-Rx cells using an antibody against
SOX2; we identified a peak in intron 15 of Ptch1, which was con-
firmed using targeted ChIP-qPCR on five independent samples.
Importantly, amplification of the Ptch1 intron 22 negative region
was equivalent when precipitated with either nonspecific IgG or
SOX2 antibody, while amplification of the intron 15 region
showed greater than fivefold enrichment in chromatin immuno-
precipitated by the SOX2-specific antibody (P < 0.01) (Fig. 5B,C).
Next, we validated the putative regulation of ptch1 by SOX2
in an in vivo context. First, we obtained a sox2 tb-MO (Kamachi
et al. 2008), and we evaluated eye size of zebrafish morphants.
Consistent with both the ocular defects observed in humans
with SOX2 mutations (Fantes et al. 2003; Chassaing et al. 2014),
as well as the ptch1 sb2 and tb-injected embryos, we observed a sig-
nificant reduction in eye area upon translational suppression of
sox2 (P < 0.001) (Fig. 3A). Further, we noted a significant defect
in optic closure in sox2morphants (62% in morphants compared
to 3.5% in controls, P < 0.001), differing from ptch1 morphant
batches, which showed amodest proportion of embryoswith colo-
boma (23.8% for ptch1 sb2, P = 0.04; 28% in ptch1 tb P = 0.012).
Next, we monitored downstream SHH pathway activity in sox2
morphants with qPCR analysis of ptch1 and gli1. We observed
significantly augmented ptch1 expression in whole-embryo lysates
from sox2morphants in comparison to controls at 2 dpf (P < 0.01)
(Fig. 5D). Notably, ptch1 and gli1 expression was also increased in
ptch1 tb-MO-injected embryos, suggesting that diminished PTCH1
protein results in overactivity of SHH signal transduction. These
data are reminiscent of the transcriptional signature observed in
vertebrate limb patterning in which SHH activation ensues after
PTCH1 inactivation (Butterfield et al. 2009). Since PTCH1 is a reg-
ulator of its own expression through SHH pathway activity (Jeong
and McMahon 2005), and SOX2 likely targets multiple SHH effec-
tors (Zhao et al. 2012), deciphering the direct versus indirect
roles of SOX2 protein on PTCH1 expression remains challenging.
Figure 4. Ptch1 transcripts are present in periocular mesenchyme and
the neural retina throughout eye morphogenesis and into post-natal life.
(A) On embryonic day (E)9.5 in transverse mouse embryo sections, anti-
sense riboprobes labeled with digoxygenin demonstrate Ptch1 expression
in cephalic mesectoderm of neural crest origin in the head (arrow) and
maxillary arch (Mx); in the basal diencephalon (Di) and basal neural
tube at trunk levels, and in the somitic sclerotome (S) and basal spinal
cord. Ectodermal expression is constant at all embryonic stages examined
(Ec). By E11.5, the distal diencephalic infundibulum transcribes Ptch1 (data
not shown) as does the subectodermal mesenchyme of the future eyelids
and palate. (C) Mesenchymal Ptch1 expression continues at E13.5, partic-
ularly in the superior and inferior palpebrae (eyelids; sPa, iPa); the lateral
neural retina (Re) and differentiated outer cells of the lens (Le) begin to
also transcribe Ptch1, which continues throughout these structures at
E15.5 (inset). By this stage, initially generalized expression in the develop-
ing cornea has become restricted to the epithelium (Co, boxes in C/inset/
D). (E) In adult mouse eyes on post-natal day 50, transcripts are found
within the outer and inner nuclear layers (Onl, Inl), corresponding to pho-
toreceptor andMüller cell bodies, and within the retinal ganglion cell layer
(Rgc), testifying to a post-natal role in retinal maintenance. Transcripts not
observed within the stroma of the anterior chamber or the sclera (Scl). (F)
Rpe, retinal pigmented epithelium; Cp; choroid plexus. Scale bar A–D,
400 µm; E, F, 200 µm. Hybridization with a sense-oriented Ptch1 probe
as negative control in B, D, F.
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However, taken together, these data suggest that PTCH1 expres-
sion can be regulated directly by SOX2 (as indicated by ChIP-
seq) and that overactivity of SHH signaling conferred through
the loss of function of either gene results in the same phenotypic
consequences of ODA.
Discussion
The SHH signaling pathway is associated strongly with ocular de-
velopment in models ranging from insects to mammals that re-
flect ∼600 million years of selection (Macdonald et al. 1995;
Chiang et al. 1996; Nasrallah and Golden 2001; Takabatake
et al. 2002; Bakrania et al. 2008; Christiansen et al. 2012). The
ptch1 zebrafish mutant displays an incompletely penetrant lens
malformation phenotype (Koudijs et al. 2005); these mutants dis-
play abnormalities at the vitreo-retinal interface resulting in mis-
shapen retinas and a reduced pupil size (Bibliowicz and Gross
2009). In addition, an ENUmutagenesis screen in zebrafish for vi-
sual system mutants identified a splice-acceptor site mutation in
ptch2 that results in ocular colobomas (Lee et al. 2013), and
ptch1;ptch2 double mutants have a severe ocular phenotype with
absent lens development at 24 hpf and completely absent eyes
at 48 hpf (Koudijs et al. 2008), phenocopying AM. Eye defects in
ptch1tj222 mutants could be suppressed by pharmacologically in-
hibiting the Hedgehog pathway with cyclopamine, providing ev-
idence in support of a direct involvement of SHH signaling in the
manifestation of the phenotype. Last, optic morphogenesis and
gene expression patterns have been compared in blind cavefish
and sighted surface fish embryos, both morphological variants
of the same Astyanax mexicanus species (Yamamoto et al. 2004).
In contrast to surface fish embryos, cavefish embryos develop
small eyeprimordia,which laterarrest indevelopment,degenerate,
and sink into the orbits, recapitulating human secondary anoph-
thalmia. An expansion of the SHH signaling domain in the pre-
sumptive ocular neuroepithelium resulted in hyperactivation of
downstream genes, lens apoptosis, and arrested eye growth and de-
velopment in cavefish embryos (Yamamoto et al. 2004). These fea-
tures could bemimicked in surface fish by shh overexpression, and
eye development was restored partially in cavefish embryos by us-
ing cyclopamine (Yamamoto et al. 2004). Recently, it has been
demonstrated that mutations in SOX11 and SMAD7 may lead to
various ODA through the activation of the SHH pathway (Zhang
et al. 2013; Pillai-Kastoori et al. 2014). In humans, PTCH1 muta-
tions have been associated previously with basal cell nevus syn-
drome (BCNS) (MIM#109400) and with holoprosencephaly
(HPE7) (MIM#610828). Of note, ODA such as AM or ASD are part
of both the BCNS (Bree and Shah 2011) and HPE (Pineda-Alvarez
et al. 2011) phenotypes.
Figure 5. SOX2 regulates Ptch1 expression directly. (A) Targeted quantitative PCR after transfection of CCE-RX cells with a scrambled siRNA (siSc, n =
9) or a siRNA targeting Sox2 (siSox2, n = 9). This experiment showed that decreased expression of Sox2 leads to increased expression of Ptch1. (B) Results
of ChIP-seq performed on CCE-RX cells using an antibody against SOX2. The Ptch1 gene structure is represented underneath the DNA fragments se-
quenced after ChIP, with higher peaks corresponding to more enrichment. A peak was identified in intron 15 of Ptch1 (underlined in black), while
an example of an unenriched region is shown in intron 22 (underlined in gray). (C) Results obtained by ChIP-seq were confirmed using targeted
ChIP-qPCR on five independent samples. Amplification of the intron 22 negative region (in gray) was equivalent whether using nonspecific IgG or a
SOX2 antibody, while amplification of the intron 15 region (in black) showed greater than fivefold enrichment in chromatin immunoprecipitated by
the SOX2-specific antibody. (A,C) Asterisks indicate statistical differences between the different conditions. (∗) P < 0.05, (∗∗) P < 0.01, (∗∗∗) P < 0.001,
Mann-Whitney U test. Error bars, SEM. (D) Quantitative (q)PCR of Shh targets ptch1 and gli1 after sox2 or ptch1 tb morpholino injection in zebrafish
embryos from three biological replicates. p1 and p2 indicate primer sets targeting two different regions of ptch1. (∗) P < 0.05, (∗∗) P < 0.01, (∗∗∗) P <
0.001, unpaired Student’s t-test.
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Our results show that the mutations identified in our ODA
cohort lead to a loss of function of PTCH1 and increased SHH sig-
naling. We also show that inhibition of SOX2 can drive overactiv-
ity of the SHH signaling pathway to produce the same ocular
phenotypic outcome.Observations fromour transient ptch1 zebra-
fish models exemplify the dosage sensitivity of PTCH1 in SHH sig-
nal transduction. The subeffective sb1 results in normal eye size
but a somite defect that canbe rescued by co-injectionwithhuman
PTCH1 mRNA; however, the efficient sb2 and tb MOs produced
both a somite defect as well as a reduction in eye area in 3-dpf
zebrafish embryos. Overexpression of human PTCH1 mRNA in
zebrafish embryos did not lead to an ocular phenotype (data not
shown), suggesting that overexpression of this SHH target gene
alone may not be sufficient to cause ODA. Moreover, although
we demonstrated that Sox2 regulates ptch1 expression, it is proba-
bly not the primary mechanism governing eye development
anomalies due to SOX2 mutations, since SOX2 is also involved
in regulation of numerous genes including ocular developmental
effectors such as PAX6, OTX2, and RAX (Hever et al. 2006;
Danno et al. 2008).
Various ocular phenotypes (microphthalmia, colobomatous
microphthalmia, and anterior segment dysgenesis) with incom-
plete penetrance are evident among our ODA cohort harboring
PTCH1 variants. Such a myriad of ocular phenotypes has already
been associated with mutations in most of the genes involved in
ODA (Slavotinek 2011), especially genes involved in the SHHpath-
way such as SHH, GLI2, and PTCH1 (Roessler et al. 2003; Ragge
et al. 2005b; Bakrania et al. 2010). The wide phenotypic spectrum
within our ODA cohort, coupled to the incomplete penetrance ob-
served among families, suggests that additional factors contribute
to the phenotype. Such factorsmay include the other 45 genes har-
boring rare variants in the initial cohort of 22 ODA samples.
However, their rarity in cases and undetectable enrichment of var-
iation in comparison to controls suggests that their contribution
will be modest; increased sample numbers and robust experimen-
tal models to test epistasis are required to demonstrate their
involvement, if any, in ODA. Finally, phenotypic variability in
ODAmay also be explained by environmental factors, as suggested
by the observation that mice heterozygous for a Ptch1 null muta-
tion had a fourfold higher risk to develop congenital malforma-
tions (including microphthalmia and anophthalmia) compared
toWTmicewhen exposed to ionizing radiation during organogen-
esis (Hahn et al. 1998). More recently, mice heterozygous for a
Ptch1 null mutation were shown to develop spontaneous cataracts
and increased susceptibility to cataract induction by early post-na-
tal exposure to ionizing radiation compared to their WT counter-
parts (De Stefano et al. 2015).
In summary, high-throughput sequencing of candidate genes
inODA identified PTCH1 as a significant contributor to congenital
ocular malformations (10% in our cohort), placing it similar to its
transcriptional regulator, SOX2, in terms of genetic burden to this
phenotypic category (Fantes et al. 2003). Importantly, this study
highlights the importance of amultifaceted approach toward iden-
tifying genetic contributors to traits such as ODA that are hall-
marked by incomplete penetrance and genetic heterogeneity,
especially when the cohort size is modest due to low disease fre-
quency in the population. This study exemplifies how, together,
a combined candidate gene sequencing approach, in vivo func-
tional assessment of allele pathogenicity, and placement to a
known disease gene network provides robust interpretive data
that would not have been possible to achieve through genetic
studies alone.
Methods
Candidate gene selection
We selected 407 candidate genes based on evidence for putative in-
volvement in ODA (Supplemental Table 1). These genes were (1)
linked to normal or abnormal ocular development in vertebrates
and/or invertebrates in the literature, or (2) likely to be regulated
by the SOX2 transcription factor according to transcriptomic
and ChIP-seq analysis.
Patients
Seventy ODA patients (22 in the discovery cohort, 48 in the repli-
cation cohort) and two positive controls with known mutations
were enrolled in this study. A signed informed consent was
obtained from each participant, which adhered to the tenets of
the Declaration of Helsinki and was approved by the local
Ethics Committee (CPP Sud-Ouest and Outre-Mer II). Ocular phe-
notypes of the 22 patients included in the first cohortwere isolated
ASD (n = 6), isolated AM (n = 4), AM with ASD (n = 6), or AM with
coloboma (n = 6) (reviewed in Supplemental Table 2). Ocular phe-
notypes of the 48 patients included in the second cohort were iso-
lated ASD (n = 14), isolated AM (n = 17), AM with ASD (n = 9), or
AM with coloboma (n = 8).
Targeted enrichment and high-throughput DNA sequencing
A custom-made SureSelect oligonucleotide probe library was de-
signed to capture the exons of 407 candidate genes (Supplemental
Table 1). The probe library also aimed to capture 880 kb of poten-
tial regulatory sequences (i.e., noncoding region located within
20 kb of the 407 genes and conserved among species). A total of
56,059 probes, covering 2.46 Mb, were designed and synthesized.
Sequence capture, enrichment, and elution were performed ac-
cording to the manufacturer’s instructions (SureSelect, Agilent).
Each eluted-enriched DNA sample was then sequenced on an
Illumina GAIIx as paired-end 75-bp reads (Integragen). Sequence
reads were aligned to the reference human genome (UCSC hg19)
using commercially available software (CASAVA1.7, Illumina)
and the ELANDv2 alignment algorithm. The mean coverage was
325× with 96.9% of the targeted sequences over 10× and 93.4%
over 25×.
Filtering strategy
All variants reported were filtered to ensure an optimal prioritiza-
tion of candidate mutations (Supplemental Table 3). We first fil-
tered out variants that did not meet the quality criteria (array
confidence < 0.3, sequence read depth < 10, and sequence base
quality < 10). We then filtered out all variants present in the local,
in-house exome sequencing database (200 exomes) as well as in
dbSNP132, 1000 Genomes Project, and the HapMap Project data-
bases. Only exonic and splice-site variants were retained; we re-
moved synonymous variants and variants predicted to be benign
by the PolyPhen-2 software. The presence of the final selected var-
iants was confirmed by Sanger sequencing.
Mutational burden analysis
We determined the mutational burden for the 10 genes identified
in the targeted resequencing of ODA samples harboring multiple
rare (<1% alternate allele frequency) functional variants (frame-
shift, nonsense, and splicing variants were considered as damag-
ing; missense variants were classified as damaging or not based
on PolyPhen-2) in ODA cases (n = 22 unknown + 2 positive
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controls) vs. Exome Variant Server controls (n = 6500). EVS was ac-
cessed in November 2013, and a χ2 test was used for comparisons.
PTCH1 molecular screening
To support further the involvement of PTCH1 lesions in ODA, we
screened this locus in a new cohort of 48 patients by direct bidirec-
tional Sanger sequencing. Primers used to amplify the 23 coding
exons and intron-exon splice junctions are listed in Supplemental
Table 7.
Zebrafish embryo microinjection and manipulation
We obtained a previously published (Koudijs et al. 2005) morpho-
lino antisense oligonucleotide (MO; GeneTools) targeting the
splice donor site of ptch1 exon 3 (sb1) and designed two additional
MOs to suppress endogenous ptch1 expression; a translation block-
er and a splice blocker targeting exon 5 (sb2). We also obtained a
previously described sox2 tb (Kamachi et al. 2008; Supplemental
Table 6). One nanoliter of the indicated cocktail was injected
intowild-type (WT) zebrafish embryos at the one- to four-cell stage
(n = 38–58 embryos/injection, repeated at least twice for MO plus
mRNA injections and seven times for ptch1 sb1 alone;withmasked
scoring).
For somite evaluation, embryos were reared at 28.5°C and im-
aged live at 36 h post-fertilization. To generate human PTCH1WT
and mutant mRNA, we first obtained a full-length open reading
frame (ORF) construct (clone ID: 100016192; OpenBiosystems).
We generated a stop codon and subsequently introduced addi-
tional nonsynonymous changes using site-directed mutagenesis
(QuikChange; Agilent). We then transferred sequenced-confirm-
ed PTCH1 ORFs into the pCS2+ plasmid (LR clonase II; Life
Technologies), linearized with NotI, and performed in vitro tran-
scription with the SP6mMessagemMachine kit (Ambion). For res-
cue experiments, 12 ng of MO and 100 pg of PTCH1 mRNA were
injected, respectively. Live embryo imaging of lateral views was
conducted on aNikonAZ100microscope at 6×magnification facil-
itated by NIS Elements software. Somite angle measurements were
taken at themidpoint between the proximal hindgut and the anus
and recorded from the resulting images using ImageJ software. For
eye sizemeasurements, embryos were fixed in 4%PFA overnight at
3 dpf, and lateral images were acquired on an SMZ745T micro-
scope facilitated by NIS Elements software. The area of the retina
and pupil was quantified using ImageJ software. Embryo batches
were compared for statistical significance using Student’s t-test.
Generation of CRISPR/Cas9 ptch1 mutants
ptch1 gRNA targeting the antisense strand of ptch1 exon 6 was pro-
duced by synthesizing and annealing two oligonucleotides,
gRNA3 F: TAGGGAAGCCCATCGGATCGAAGT and gRNA3 R:
AAACACTTCGATCCGATGGGCTTC. The annealed oligos were
then ligated to a BsmBI-digested T7cas9sgRNA2 vector overnight
at room temperature (NEB). Two microliters of the reaction were
used for transformation. Prior to transcription, the gRNA vector
was linearized with BamHI. gRNA was transcribed using the
MEGAshortscript T7 kit (AM1354, Life Technologies) and purified
using alcohol precipitation. A total of 150 pg of ptch1 gRNA and
300pg of Cas9 protein (PNA Bio) were co-injected into single
cells of one-cell stage embryos. For the T7 endonuclease I assay,
genomic DNA was prepared from 1-dpf embryos by digestion in
5 µg/mL proteinase K for 90 min at 65°C, followed by 15 min at
95°C. A short stretch of the genomic region (∼150 bp) flanking
the ptch1 gRNA target site was PCR-amplified from the genomic
DNA (Fwd: TAGTGGCAAACCCCCATTAC, Rev: CCTTGACCCAC
ATCTGCTTT). The PCR amplicon was then denatured slowly
and reannealed to facilitate heteroduplex formation. The rean-
nealed amplicon was then digested with 5 units of T7 endonucle-
ase I (New England Biolabs) at 37°C for 90 min. The samples were
resolved by electrophoresis and ethidium bromide staining in a
3.0% agarose gel. PCR products were cloned (TOPO-TA cloning,
Life Technologies), and individual colonies were sequenced to
determine insertion-deletion sites and to estimate the extent of
mosaicism in F0 founders.
Chromatin immunoprecipitation (ChIP)
We performed quantitative ChIP-seq in murine stem cells geneti-
cally modified to overexpress Rax (retina and anterior neural fold
homeobox) (CCE-Rx cells, a kind gift from S. Watanabe) (Tabata
et al. 2004). These cells have the ability to differentiate into retinal
ganglion cells and were cultured using the standard procedures
(Tabata et al. 2004). Two × 106 resuspended CCE-Rx cells were cul-
tured in LIF-free medium on 10-cm bacterial plates. Forty-eight
hours later, CCE-Rx embryoid bodies were treated with formalde-
hyde for 10min, chromatinwas prepared, andChIPwas performed
according to the Upstate (Millipore) protocol, using 10 μg of anti-
SOX2 antibody (sc-17320, Santa Cruz Biotechnology) or mouse
IgG (PP54, Millipore) as a control. ChIP-seq libraries were prepared
and sequenced using the standard Illumina protocol. Peaks were
called with SeqMonk using the contig generator function. Inside
intron 15 of Ptch1, a peak was identified in the SOX2-immunopre-
cipitated sample. The online JASPAR database (http://jaspar.
genereg.net/; Mathelier et al. 2014) confirmed the presence of a
putative SOX2 binding site within the peak sequence. Amplicons
corresponding to the Ptch1 intron 15 SOX2 ChIP-seq peak and to
a regionnotpredicted tobind SOX2 in intron22 (see Supplemental
Table 8 for primers) were selected for validation. These amplicons
were tested in five independent samples immunoprecipitated ei-
ther with SOX2 or mouse IgG antibodies.
Quantitative RT-PCR
Quantitative PCR analysis was performed in CCE-Rx cells and
zebrafish embryos to confirm Ptch1 regulation by SOX2. CCE-Rx
cells were cultured using the standard procedures (Tabata et al.
2004) and transfected as previously described (Ko et al. 2009) ei-
ther with an siRNA targeting Sox2 mRNA or with a scrambled
siRNA (Stealth siRNA MSS277200 and Negative Control Medium
GC, respectively, Invitrogen). Quantitative real-time PCR analyses
on complementary DNA transcribed from total RNA showed that
the remaining Sox2 expression was 50% at 24 h post-transfection
and 75% at 48 h post-transfection. Forty-eight hours after transfec-
tion of either the siSOX2 (n = 9) or the siScramble (n = 9), total RNA
was isolated using the GenElute Mammalian Total RNA Miniprep
kit (Sigma-Aldrich). Samples were used to analyze Ptch1 expression
levels in the siSox2 samples compared to controls (Supplemental
Table 8 for primers). Zebrafish embryos injected with 1.5 ng
ptch1 tb MO or 2.5 ng sox2 tb MO were grown for 48 h before iso-
lation of total RNA using TRIzol (Invitrogen) following the manu-
facturer’s protocol. cDNA was synthesized from 1 μg of total RNA
using SuperScript III (Invitrogen). Real-time PCR was performed
with Power SYBR Green PCR Master Mix on a 7900HT (Applied
Biosystems) and analyzed with a Sequence Detection System soft-
ware package version 2.3 (Applied Biosystems) (Supplemental
Table 8 for primers).
In situ hybridization
In situ hybridization was carried out according to standard proto-
cols (Goodrich et al. 1996) on paraffin sections using a murine
digoxygenin-labeled Ptch1 riboprobe (Chotteau-Lelievre et al.
PTCH1 contributes to ocular developmental anomalies
Genome Research 483
www.genome.org
 Cold Spring Harbor Laboratory Press on June 20, 2017 - Published by genome.cshlp.orgDownloaded from 
2006) synthesized in antisense and sense (negative control)
orientations.
Data access
The data from transcriptomic and ChIP-seq from this study have
been submitted to the NCBI Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/geo/) under accession number
GSE74600. All variants identified during this study have been sub-
mitted to the ClinVar database (www.ncbi.nlm.nih.gov/clinvar;
Landrum et al. 2016), and ClinVar accession numbers are listed
in Table 1 (PTCH1 variants identified in ODA patients) and in
Supplemental Table S4 (final prioritized variants in patients with
ODA).
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